Taken together, this evidence suggests that the use of direct anticoagulants and, in general, of serine proteases inhibitors, including gliptins and possibly chymase inhibitors, might be included within the armamentarium of the pharmacological treatment for AF. The gene discussed is CMA1; the disease is atrial fibrillation.